269P - Outcomes of systemic therapy for advanced triple-negative breast cancer: a single centre experience.

Date 11 September 2017
Event ESMO 2017 Congress
Session Poster display session
Topics Anti-Cancer Agents & Biologic Therapy
Breast Cancer, Metastatic
Breast Cancer
Presenter Nicolò Battisti
Citation Annals of Oncology (2017) 28 (suppl_5): v74-v108. 10.1093/annonc/mdx365
Authors N. Battisti1, D. Okonji1, T. Manickavasagar1, K. Mohammed2, M. Allen1, A. Ring1
  • 1Breast Unit, The Royal Marsden NHS Foundation Trust, SW3 6JJ - London/GB
  • 2Research And Development Department, The Royal Marsden NHS Foundation Trust, SW3 6JJ - London/GB

Abstract

Background

Systemic treatment outcomes for advanced triple-negative breast cancer (aTNBC) are worse compared to other disease subtypes, due to aggressive behaviour, heterogeneity and lack of molecular targets. Many options are under investigation although most patients receive standard cytotoxic chemotherapy. We aimed to provide better insight into the efficacy of different lines of therapy for aTNBC (overall response rate [ORR], median progression-free survival [mPFS] and median overall survival [mOS]) to better inform discussion with patients, decision-making and referral for clinical trials.

Methods

We retrospectively identified 268 patients diagnosed with aTNBC from 01/12/2011 to 30/11/2016 from our electronic records. Patients’ and tumour characteristics were recorded, along with systemic treatment outcomes. Chi-squared/Fishers exact test and Kaplan-Meier statistical methods were utilised.

Results

186 patients treated with ≥1 line of palliative systemic treatment were eligible for the analysis with a median age at 55 (range 26-91). 53.8% had ECOG Performance Status 0 and 69.9% visceral involvement. 38.6% had a disease-free interval (DFI)

Conclusions

The response rates observed in this population of patients are similar to those observed in published clinical trials. However, the PFS rates are short, and as a result early consideration for inclusion in clinical trials of novel approaches can be justified in these patients.

Clinical trial identification

Legal entity responsible for the study

Nicolò Matteo, Luca Battisti

Funding

None

Disclosure

All authors have declared no conflicts of interest.